Clinical Trials Logo

Depression clinical trials

View clinical trials related to Depression.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT03328520 Enrolling by invitation - Depression Clinical Trials

WILD 5 Wellness, A 30-Day Intervention

Start date: October 24, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in First Year Beloit College students self-selected into a wellness focused first year initiative. This program is called "WILD 5 Wellness: A 30-Day Intervention".

NCT ID: NCT03327259 Enrolling by invitation - Depressive Symptoms Clinical Trials

Imaginal Exposure and Activity Planning for Depressive Symptoms

Start date: October 9, 2017
Phase: N/A
Study type: Interventional

There is literature to support both the need for and efficacy of brief interventions for depressive symptoms, particularly among college students. Brief behavioral activation interventions (BATD) have gained recognition as efficacious treatments for depression. In accordance with behavioral models of depression, the treatment involves increasing activity and positive experience, to break the negative reinforcement cycle maintaining depressed mood. This treatment does not, however directly target emotional avoidance, which may interfere with individuals' ability to engage in and benefit from rewarding activities assigned to patients as therapeutic activities. Imaginal exposure, a treatment commonly used for the treatment of anxiety disorders, has demonstrated efficacy and may serve to reduce emotional avoidance, making it easier for individuals with higher emotional avoidance to partake in and benefit from therapeutic activities. Evidence of symptom and treatment overlap between anxiety and depression, informs this intervention, which incorporates treatment techniques developed for both disorders. The goal of this study is to compare, in a randomized control trial, the effects of a single session of Activity Planning Only to Imaginal Exposure Augmented Activity Planning. Specifically, the investigators are interested in seeing if adding imaginal exposure improves self-efficacy and goal attainment.

NCT ID: NCT03324906 Enrolling by invitation - Obesity Clinical Trials

Effects of Transcranial Direct Current Stimulation (tDCS) on Individuals With Prader-Willi Syndrome

Start date: May 8, 2017
Phase: N/A
Study type: Interventional

Prader-Willi Syndrome (PWS) is a multisystemic genetic disease characterized by hypotonia, mental retardation, hyperphagia, and uncontrollable hunger due to hypothalamic dysfunction, caused by dysregulation of genes located in chromosome 15q11-q13. The goal of this study is to evaluate the effects of Transcranial Direct Current Stimulation (tDCS) on hyperphagia and behavior in PWS. Forty children and adolescents (11-24 years) with clinical and cytogenetic-molecular diagnosis of Prader-Willi syndrome will be assessed before and after 10 tDCS session with: Food Craving Questionnaire (FCQ), Aberrant Behavior Checklist (ABC), Dykens hyperphagia questionnaire. Caregivers self-reported the participant's behaviors at home and, lately, they will be categorized and quantified. tDCS will be applied for 20 minutes with electrodes of 25cm2 wrapped in cotton material soaked in saline solution. The anode at the left dorsolateral prefrontal cortex (F3) and the cathode at the contralateral area (F4). Children from 11-12 years will receive a current of 1mA; above 13 years, 2mA.

NCT ID: NCT03290963 Enrolling by invitation - Clinical trials for Treatment Resistant Depression

Effect of Lithium Versus Placebo in Adults With Treatment-Resistant Depression Who Are Receiving Ketamine

Start date: March 2018
Phase: Phase 2
Study type: Interventional

The purpose of this research study is to compare the antidepressant effect of lithium versus placebo in adults receiving ketamine. Lithium is available commercially for depression; ketamine is available commercially and can help the symptoms of depression; however, it has not been approved by the U.S. Food and Drug Administration (FDA) for this use. The FDA has allowed the use of this drug in this research study.

NCT ID: NCT03277846 Enrolling by invitation - Depression Clinical Trials

The Safety and Efficacy of Nexalin Trans-cranial Electrical Stimulation Stimulation for the Treatment of Depression

TES
Start date: September 1, 2017
Phase: N/A
Study type: Interventional

The purpose of this research study is to determine whether Nexalin Trans-cranial Electrical Stimulation (TES) is an effective treatment for depression among patients who are candidates for ECT. A secondary aim to assess whether Nexalin can be used as an alternative to ECT. Although Nexalin has been approved for use in the US, using Nexalin to treat depression in this way is investigational and experimental. If Nexalin is found to be an alternative to ECT, it could offer a safer treatment for depression with less side-effects and a lower cost.

NCT ID: NCT03275571 Enrolling by invitation - HIV Infections Clinical Trials

HIV, Computerized Depression Therapy & Cognition

Start date: September 6, 2017
Phase: N/A
Study type: Interventional

Among people with HIV, the severity of depressive symptoms has repeatedly been associated with the presence of self-reported cognitive difficulties, even in the absence of impairment on neuropsychological testing. There is uncertainty about the clinical importance of these self-reports, especially when neuropsychological testing is normal. However, there is growing evidence that these self-reports are clinically important. For example, among patients with major depressive disorder (MDD), evidence suggests that functional impairments is mediated by self-reported cognitive dysfunction, rather than objective cognitive dysfunction. Treatment of depression with Cognitive-Behaviour Therapy (CBT) has been shown to improve depressive symptoms and psychosocial functioning in patients with recurrent major depressive disorder, but there are few studies of the impact of psychotherapy on self-reported cognition and cognitive performance. Good Days Ahead (GDA) is a computerized treatment program developed to address symptoms of depression and anxiety. It teaches the basic principles of computerized behavioral therapy (CBT) in nine therapy sessions, each typically taking 30 minutes to complete. GDA has been found to be as effective as face-to-face CBT in decreasing symptoms of depression and anxiety. The hypothesis is that people whose depressive symptoms are reduced following treatment with cCBT will also report fewer cognitive difficulties than before treatment. A second hypothesis is that changes in self-reported cognition will be concordant with changes in cognitive performance, such that people who make no improvement in self-report cognition will also show no improvement in cognitive performance and those who do improve on self-report will improve on cognitive performance.

NCT ID: NCT03272555 Enrolling by invitation - Depression Clinical Trials

WILD 5 Wellness: A 30-Day Intervention

Start date: September 5, 2017
Phase: N/A
Study type: Interventional

The purpose of this study is to explore the efficacy and feasibility of an integrated, prescriptive, and trackable wellness intervention combining five wellness elements including exercise, mindfulness, sleep, social connectedness, and nutrition in First Year Beloit College students self-selected into a wellness focused first year initiative.

NCT ID: NCT03260985 Enrolling by invitation - Depressive Symptoms Clinical Trials

Precision Psychiatry Continuity Clinic Project

Start date: July 25, 2017
Phase: N/A
Study type: Interventional

This is a demonstration project focused on translating neuroscience insights into clinical practice. The researchers will evaluate how neuroscience assessments may be applied in the clinical setting to help inform care decisions. The aim of the study is to undertake a pragmatic pilot trial to assess whether the inclusion of structured feedback from neuroscience assessments has an effect on improving patient outcomes. The study will investigate how neuroscience assessments can be integrated into and improve clinical care. The impact of sharing information and conclusions from these assessments with psychiatric providers will be explored. Outcomes will include symptoms, social/occupational function and qualify of life.

NCT ID: NCT03240692 Enrolling by invitation - Clinical trials for Treatment Resistant Depression

Accelerated Theta Burst Stimulation in Treatment-Resistant Depression

aTBS
Start date: May 1, 2017
Phase: N/A
Study type: Interventional

This study evaluates an accelerated schedule of theta-burst stimulation using a transcranial magnetic stimulation device for treatment-resistant depression. In this open label study, all participants will receive accelerated theta-burst stimulation.

NCT ID: NCT03210155 Enrolling by invitation - Depression Clinical Trials

Efficacy of CES in New Mothers During the Post Partum Period

Start date: July 24, 2017
Phase: N/A
Study type: Interventional

The birth of a child is a major life event that can be filled with excitement, anticipation and joy. However, the transition and adaptation to new demands, roles, responsibilities, and changes in relationships can be stressful, especially for new mothers. In addition, new mothers typically encounter physiological changes and struggle with concerns about weight gain, body image, sexuality, and other physical difficulties such as fatigue. These problems may generate or exacerbate stress, lead to an actual or perceived crisis and psychological distress. Psychological distress, defined as anxiety, depression, and insomnia, in this study, often increases during the postpartum period and can negatively affect maternal mental health status, maternal and family relationships, and infant-child health. The purpose of this study is to evaluate the effects of cranial electrotherapy stimulation (CES) on anxiety, insomnia, depression, and maternal functioning in first time new mothers following childbirth.